Skip to main content

Table 1 Subject details of patients receiving radionuclide therapy with [177 Lu]Lu-DOTAZOL

From: Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results

 PT1PT2PT3PT4MeanSD
Age8366646469.259.22
BSA1.9221.9761.9791.9791.9640.028
Hemoglobin (g/dl)14.39.613.112.612.42
Thrombocytes (G/l)18739422618924998.32
Leucocytes (G/l)5.479.775.373.355.992.70
Hematocrit0.40.40.40.370.390.02
Dose (MBq)60006000587360005968.2563.50
TumormCRPCmCRPCBronchial carcinomaBronchial carcinoma  
Previous therapies receivedDegarelix/denusumab [17777Lu]Lu-PSMA-617Local Irradiation/docetaxel leuprorelin acetate, abiraterone/denosumabCarboplatin/denosumab, nivolumabCarboplatin/denosumab, nivolumab  
Extent of metastasesExtensiveExtensiveExtensiveExtensive  
ECOG status0000